Cardiovascular disease is the number one killer in UK and in most of the Western countries. It is already a huge burden to healthcare systems around the world, and improvements in the prevention, diagnosis, and effective treatment will be among the most pressing challenges within our aging populations in this century.
We will transform Cambridge into a world-leading hub for cardiovascular research. The foundation for this is provided through the integration of high quality pre-clinical and clinical research operating in a University-Hospital-Industry partnership. This partnership, now based in the VPD Heart & Lung Research Institute, is being driven by the re-location of the Royal Papworth Hospital and AstraZeneca global HQ and R&D facilities to the Cambridge Biomedical Campus.
